<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    Why did SNDX's operating expenses surge in Q4 2024?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        5/7/2025 06:41pm
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">SNDX's operating expenses for Q4 2024 are not currently available. However, we can infer that any significant increases in operating expenses would likely be related to strategic initiatives or investments in the company's product pipeline and commercial operations. The company's focus on expanding market presence and pursuing regulatory approvals for its products could contribute to higher operating expenses in the near term.</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am,an){return {layout:"default",data:[{noData:c,currentQuestion:d,textDescription:D,comeFrom:"AInvestShareLink",events:[],answerSource:l}],fetch:{},error:m,state:{sharePreviewModule:{loadJgySuccess:i,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:1,agent_id:a,output_media_info:[],task_id:a,language:a,source:l,cache_builder:a,reply_action:"Answer",execute_mode:w,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"Why did SNDX's operating expenses surge in Q4 2024?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"Why did SNDX's operating expenses surge in Q4 2024?\",\"user_id\":\"dp29015577\",\"user_name\":\"\",\"trace_id\":\"1e1f692c-9a96-4957-bb2d-26895efa0be1\",\"session_id\":\"1e1f692c-9a96-4957-bb2d-26895efa0be1\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"search",raw_data:{number:E,title:F,summary:G,full_summary:"Earnings Call Insights: Syndax Pharmaceuticals (SNDX) Q1 2025 Management View CEO Michael Metzger highlighted that Syndax achieved $34 million in combined net sales for Revuforj and Niktimvo during Q1 2025. Revuforj's net revenue reached $20 million, while Niktimvo, through partner Incyte, reported $13.6 million in net revenue for the first two months of its launch. Syndax has a strong cash position of $602.1 million as of March 31, 2025, enabling the company to pursue its strategic objectives. The EVOLV-2 trial, a pivotal frontline study of revumenib for newly diagnosed mutant mNPM1 and KMT2A AML patients, has begun. Metzger confirmed plans to amend the trial protocol to include dual primary endpoints of complete remission and overall survival. CFO Keith Goldan detailed that Syndax’s share of Niktimvo's net commercial loss was $200,000 for Q1 2025, with expectations of transitioning to positive revenue contributions in subsequent quarters. Chief Commercial Officer Steve Closter shared that Revuforj has seen strong adoption, with 44% of Tier 1 and Tier 2 accounts ordering by the end of March 2025. Outlook Syndax expects continued growth in coverage and reimbursement for Revuforj, which currently has formulary coverage for 72% of managed care lives. The company anticipates a potential FDA approval for Revuforj's second indication in relapse or refractory mutant mNPM1 AML by year-end 2025. The sNDA is under review with priority review likely. The EVOLV-2 trial's design supports accelerated and full approval pathways in the frontline setting. Revuforj is poised to expand its market presence, with a total addressable market exceeding $4 billion across relapsed\u002Frefractory and frontline AML populations. Financial Results Revuforj generated $20 million in net revenue during Q1 2025, its first full quarter of sales since launch. Niktimvo recorded $13.6 million in net revenue, with Syndax recognizing a $200,000 net commercial loss share. Syndax reported strong formulary cove",url:H,image_url:a,video_url:a,publish_time:I,search_extra_info:{search_burial_info:{id:n,uid:n,ab:{scene_id:J,layer_exp:[{layer_id:K,exp_id:L}]}}},simhash:"2d8d5e27fb44a163",msg_id:n}}],answer_chain_name:M,agent_mode:N,native_answer:a,come_from:a,text_answer:D,trace_id:e,cost:15486,event_names:a,question:d,fallback_type:O,input_type:P,fall_back_reason:{fall_back_type:O,may_fall_back_reason:"UNKNOWN",risk_detail:{matched_words:[]}},session_id:e,first_return_cost:4111,cache_type:"no_cache",question_id:e,transfer_question:d,signal_type:"ON_COMPLETE",start_time:Q,remote_svc:l,slots:[],answer_type:w,user_id:s,skill_name:x},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:e,session_id:e,user_id:s,question:d,source:l,raw_question:d,version:"3.4.1",action_name:x,nlu:{entity:[{type:R,value:"SNDX.O",market:S}]},deep_research:c,deep_thinking:c,agent_mode:N},extra:{}},{answer_path:f,section:{id:g,info_texts:["Thinking"],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:f,section:{id:g,info_texts:["Querying Stock: SNDX Operating Expenses in Q4 2024"],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b,status:t},logs:[],extra:{action:T,action_input:"SNDX Operating Expenses in Q4 2024",thought:u}},{answer_path:f,section:{id:g,info_texts:["Querying Stock: SNDX GICS Industry"],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b,status:t},logs:[],extra:{action:T,action_input:"SNDX GICS Industry",thought:u}},{answer_path:f,section:{id:g,info_texts:["Searching Web: Why did SNDX Operating Expenses Surge in Q4 2024"],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b,status:t},logs:[],extra:{action:U,action_input:"Why did SNDX Operating Expenses Surge in Q4 2024",thought:u}},{answer_path:f,section:{id:g,info_texts:["Searching Web: Syndax Analysis"],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b,status:t},logs:[],extra:{action:U,action_input:"Syndax Analysis",thought:u}},{answer_path:j,section:{id:V,info_texts:[],show_type:y,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:j,section:{id:V,info_texts:[],show_type:y,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:g,info_texts:["Generating Answer"],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:j,section:{id:z,info_texts:[],show_type:A,voice_txt:"S",text_answer:W,rich_text:W,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:j,section:{id:2000,info_texts:[],show_type:A,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:H,image_url:a,video_url:a,title:F,summary:G,index:E,publish_time:I,search_id:n,search_uid:n,search_ab:{scene_id:J,layer_exp:[{layer_id:K,exp_id:L}]},jump_type:"normal"}],is_last:b},logs:[],extra:{}},{answer_path:j,section:{id:z,info_texts:[],show_type:A,voice_txt:". The",text_answer:X,rich_text:X,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:j,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:Y,market_id:S,name:"Syndax",domain:R},pos:i,section_id:z,txt:Y,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:g,info_texts:["Completed"],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:o,query_text:o,trace_info:{item_id:"5f34160bc3d2d0a4788a476ed9427fff",item_type:k,item_name:o,rec_info:Z}},{display_text:p,query_text:p,trace_info:{item_id:"bba126c7b0ab6d5971f4a0911c900111",item_type:k,item_name:p,rec_info:_}},{display_text:q,query_text:q,trace_info:{item_id:"35fa1f06a9a467026c2f5e70a9644a63",item_type:k,item_name:q,rec_info:$}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:c,txt_style:i,type:"1",display2:c,url:a}},request_config:[{source_type:aa,related_name:ab}],puuid:B,tag:a,category:"custom",uuid:ac}],global:{urp_static_data:[{name:ab,value:{status_code:i,columns:[{type:r,index_name:ad,key:ad},{type:r,index_name:ae,key:ae},{type:r,index_name:af,key:af},{type:r,index_name:ag,key:ag},{type:r,index_name:ah,key:ah}],datas:[{send_text:o,item_type:k,rec_info:Z,display_text:o,rec_reason:a},{send_text:p,item_type:k,rec_info:_,display_text:p,rec_reason:a},{send_text:q,item_type:k,rec_info:$,display_text:q,rec_reason:a}],dataSize:aa,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:ai,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:v,"min-height":"100%",position:aj,height:v},isMaterial:c,id:ai,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:i,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:C,componentUuid:ac,script:[{name:ak,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:C,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:C},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:v,position:aj,height:v},isMaterial:b,_id:19,id:ak,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:al,voice_txt:a,tracking_info:{},uuid:B},order:{is_auto:c,render_for:al,chart_type:"command",puuid:B}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1005,info_texts:[],show_type:y,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:x,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:w,answer_chain_name:M},is_deep_research:c,deep_thinking:c,create_time:1746614500807},is_last:b}],questionItem:{data:{qStr:d,encodeFlag:c,imageData:m,docsData:[],quoteData:m},tplType:"question"},events:am,agentId:a,param:{entity_info:{},add_info:{ori_question:d},event_list:am,client_ip:a,question:d,user_id:s,user_name:a,trace_id:e,session_id:e,source:l,input_type:P}}],userId:s,userName:a,startTime:Q,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:m,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:i,traceTableData:m,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fwhy-did-sndxs-operating-expenses-surge-in-q4-2024-1deab3\u002F",config:{_app:{basePath:an,assetsPath:an,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"Why did SNDX's operating expenses surge in Q4 2024?","1e1f692c-9a96-4957-bb2d-26895efa0be1","progress\u002Fsearching_for",1000,"searching_for",0,"other\u002FopenAnswer","llm_generated","ths_ainvest_lite_web",null,"b02f6bad31fb70bc","📊 How did SNDX's revenue change in Q4 2024 compared to previous quarters?","🏆 What were SNDX's key business developments in Q4 2024?","📈 How do analysts interpret SNDX's Q4 2024 financial results?\n\u003C|im_end|\u003E","STR","dp29015577","thinking","The user wants to analyze why SNDX's operating expenses increased significantly in Q4 2024. I should focus on SNDX's operating expense data and information about its business, industry, and market analyses of the surge. I will use FinQuery for the data mentioned above; use Search for the reasons behind the surge and market analyses.","auto","agent","explain news events","signal",2001,"rich_text","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","SNDX's operating expenses for Q4 2024 are not currently available. However, we can infer that any significant increases in operating expenses would likely be related to strategic initiatives or investments in the company's product pipeline and commercial operations. The company's focus on expanding market presence and pursuing regulatory approvals for its products could contribute to higher operating expenses in the near term.",10,"Syndax signals $4B total market opportunity with Revuforj expansion into frontline settings","Earnings Call Insights: Syndax Pharmaceuticals (SNDX) Q1 2025 Management View CEO Michael Metzger highlighted that Syndax achieved $34 million in combined net sales for Revuforj and Niktimvo during Q1 2025. Revuforj's net revenue reached $20 million, while Niktimvo, through partner Incyte, reported ...","https:\u002F\u002Fseekingalpha.com\u002Fnews\u002F4441527-syndax-pharmaceuticals-outlines-750m-opportunity-for-revuforj-in-initial-market","2025-05-05","oeqxkhszf","oeqxkhszf_layer","base","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite",1746614485321,"stock","185","Querying Stock","Searching Web",999,"SNDX's operating expenses for Q4 2024 are not currently available. However, we can infer that any significant increases in operating expenses would likely be related to strategic initiatives or investments in the company's product pipeline and commercial operations[^10]",". The company's focus on expanding market presence and pursuing regulatory approvals for its products could contribute to higher operating expenses in the near term[^10].","SNDX","2+679_496_21_554+0+0+1e1f692c-9a96-4957-bb2d-26895efa0be1+5f34160bc3d2d0a4788a476ed9427fff+llm_generated+aimeTagAnalysis+0+0.051253773272037506+1","2+679_496_21_554+0+0+1e1f692c-9a96-4957-bb2d-26895efa0be1+bba126c7b0ab6d5971f4a0911c900111+llm_generated+aimeTagAnalysis+0+0.043509550392627716+2","2+679_496_21_554+0+0+1e1f692c-9a96-4957-bb2d-26895efa0be1+35fa1f06a9a467026c2f5e70a9644a63+llm_generated+aimeTagAnalysis+0+0.03604639321565628+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>